Brief: Ultimovacs Announces Positive Topline Results From Phase I Combination Trial Evaluating Universal Cancer Vaccine, Uv1, In Malignant Melanoma Patients
30/09/2020 17:45
Sept 30 (Reuters) - Ultimovacs ASA ULTIMO.OL :
* ULTIMOVACS ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE I
COMBINATION TRIAL EVALUATING UNIVERSAL CANCER VACCINE, UV1, IN
MALIGNANT MELANOMA PATIENTS
* ULTIMOVACS ASA - RESULTS CONFIRM ACHIEVEMENT OF PRIMARY
ENDPOINTS OF SAFETY AND TOLERABILITY
* ULTIMOVACS ASA - NONE OF PATIENTS EXPERIENCED UNEXPECTED
SAFETY
ISSUES RELATED TO UV1 AND VACCINE WAS WELL-TOLERATED
Source text for Eikon: ID:nBw7rqBW9a
Further company coverage: ULTIMO.OL
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zelluna ASA
See all newsNorway's Zelluna ASA reports Q2 loss
Brief: Zelluna Reports Q2 Total Loss Of NOK 19.7 Million
Brief: Zelluna Says IDMC Recommends Recruitment Of Next Two Patients At First Dose Level
Brief: Zelluna Says First Patient Dosed With Zi-Ma4-1 In Zima-101 Phase 1 Trial
Brief: Zelluna Wins NOK 16 Mln Research Council Of Norway Grant